Ronald B. Langdon

2.8k total citations
45 papers, 2.2k citations indexed

About

Ronald B. Langdon is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ronald B. Langdon has authored 45 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Cellular and Molecular Neuroscience and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ronald B. Langdon's work include Neuroscience and Neuropharmacology Research (12 papers), Diabetes Treatment and Management (11 papers) and Metabolism, Diabetes, and Cancer (9 papers). Ronald B. Langdon is often cited by papers focused on Neuroscience and Neuropharmacology Research (12 papers), Diabetes Treatment and Management (11 papers) and Metabolism, Diabetes, and Cancer (9 papers). Ronald B. Langdon collaborates with scholars based in United States, Japan and Netherlands. Ronald B. Langdon's co-authors include Mriganka Sur, Jong‐On Hahm, Keith D. Kaufman, John M. Amatruda, Anjuli Nayak, Peter P. Stein, Robert S. Jacobs, John A. Freeman, Ya‐Ping Tang and David Shrom and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ronald B. Langdon

45 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronald B. Langdon United States 25 808 769 730 382 313 45 2.2k
Mark H. Perrone United States 30 1.2k 1.4× 543 0.7× 713 1.0× 455 1.2× 600 1.9× 81 3.3k
Liying Han China 21 943 1.2× 347 0.5× 540 0.7× 221 0.6× 1.4k 4.4× 51 3.2k
Weimin He China 18 1.8k 2.3× 283 0.4× 358 0.5× 267 0.7× 1.2k 3.8× 63 3.5k
Kalindi Bakshi United States 10 777 1.0× 351 0.5× 589 0.8× 144 0.4× 1.0k 3.2× 12 2.1k
Mohammad M. Khan United States 21 525 0.6× 349 0.5× 487 0.7× 105 0.3× 279 0.9× 38 2.2k
Émilie Faivre France 18 603 0.7× 625 0.8× 574 0.8× 266 0.7× 715 2.3× 29 2.1k
Sravan K. Goparaju Japan 21 1.1k 1.4× 566 0.7× 671 0.9× 478 1.3× 570 1.8× 24 3.4k
Kendra K. Bence United States 34 2.3k 2.9× 567 0.7× 403 0.6× 511 1.3× 1.4k 4.5× 57 4.7k
Bhumsoo Kim United States 25 1.0k 1.3× 561 0.7× 423 0.6× 168 0.4× 1.0k 3.3× 37 2.6k
Ronald W. Irwin United States 22 981 1.2× 504 0.7× 587 0.8× 68 0.2× 961 3.1× 35 2.6k

Countries citing papers authored by Ronald B. Langdon

Since Specialization
Citations

This map shows the geographic impact of Ronald B. Langdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald B. Langdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald B. Langdon more than expected).

Fields of papers citing papers by Ronald B. Langdon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald B. Langdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald B. Langdon. The network helps show where Ronald B. Langdon may publish in the future.

Co-authorship network of co-authors of Ronald B. Langdon

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald B. Langdon. A scholar is included among the top collaborators of Ronald B. Langdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald B. Langdon. Ronald B. Langdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fonseca, Cândida, Aldo P. Maggioni, Filipa Marquês, et al.. (2017). A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. International Journal of Cardiology. 250. 215–222. 3 indexed citations
2.
Tatosian, Daniel, Ying Guo, Andrea Schaeffer, et al.. (2013). Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin. Diabetes Therapy. 4(2). 431–442. 38 indexed citations
3.
Seiberling, Michael, et al.. (2013). Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30days with MK-7123, a selective CXCR2 antagonist. International Immunopharmacology. 17(2). 178–183. 10 indexed citations
4.
Futamura, Mayumi, Jun Yao, Raynald Bergeron, et al.. (2012). Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia. 55(4). 1071–1080. 33 indexed citations
5.
Statkevich, Paul, Teddy Kosoglou, Richard A. Preston, et al.. (2012). Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. European Journal of Clinical Pharmacology. 68(11). 1501–1508. 22 indexed citations
6.
7.
Kosoglou, Teddy, Walter K. Kraft, Paul Statkevich, et al.. (2012). Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. European Journal of Clinical Pharmacology. 68(7). 1049–1056. 26 indexed citations
8.
Shah, Sukrut, Anne Hermanowski‐Vosatka, Gang Jia, et al.. (2011). Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension. 5(3). 166–176. 76 indexed citations
9.
Eiki, Jun‐ichi, Yasufumi Nagata, Mayumi Futamura, et al.. (2011). Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs. Molecular Pharmacology. 80(6). 1156–1165. 25 indexed citations
10.
Peier, Andrea, James Hubert, Xiaobing Du, et al.. (2011). Effects of Peripherally Administered Neuromedin U on Energy and Glucose Homeostasis. Endocrinology. 152(7). 2644–2654. 48 indexed citations
11.
Herman, Gary, Goutam C. Mistry, Bingming Yi, et al.. (2010). Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology. 71(3). 429–436. 29 indexed citations
12.
Ohyama, Sumika, Hiroki Takano, Tomoharu Iino, et al.. (2010). A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. European Journal of Pharmacology. 640(1-3). 250–256. 18 indexed citations
13.
Mohan, Viswanathan, Wenying Yang, Ho‐Young Son, et al.. (2008). Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Research and Clinical Practice. 83(1). 106–116. 134 indexed citations
14.
Philip, George, David S. Pearlman, César Villarán, et al.. (2007). Single-Dose Montelukast or Salmeterol as Protection Against Exercise-Induced Bronchoconstriction. CHEST Journal. 132(3). 875–883. 36 indexed citations
15.
Nayak, Anjuli & Ronald B. Langdon. (2007). Montelukast in the Treatment of Allergic Rhinitis. Drugs. 67(6). 887–901. 100 indexed citations
16.
Feng, Ruiben, Claire Rampon, Ya‐Ping Tang, et al.. (2001). Deficient Neurogenesis in Forebrain-Specific Presenilin-1 Knockout Mice Is Associated with Reduced Clearance of Hippocampal Memory Traces. Neuron. 32(5). 911–926. 372 indexed citations
17.
Langdon, Ronald B. & Mriganka Sur. (1992). The effects of selective glutamate receptor antagonists on synchronized firing bursts in layer III of rat visual cortex. Brain Research. 599(2). 283–296. 8 indexed citations
18.
Langdon, Ronald B., Jamie Johnson, & Germán Barrionuevo. (1991). Time course and plasticity of rat hippocampal ca3 pyramidal cell responses to input from recurrent collaterals examined by whole cell recordings. The Society for Neuroscience Abstracts. 17. 1330. 1 indexed citations
19.
Hahm, Jong‐On, Ronald B. Langdon, & Mriganka Sur. (1991). Disruption of retinogeniculate afferent segregation by antagonists to NMDA receptors. Nature. 351(6327). 568–570. 225 indexed citations
20.
Langdon, Ronald B., Paul B. Manis, & John A. Freeman. (1988). Goldfish retinotectal transmission in vitro: component current sink-source pairs isolated by varying calcium and magnesium levels. Brain Research. 441(1-2). 299–308. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark H. Perrone Breakdown of academic impact, for papers by Liying Han Breakdown of academic impact, for papers by Weimin He Breakdown of academic impact, for papers by Kalindi Bakshi Breakdown of academic impact, for papers by Mohammad M. Khan Breakdown of academic impact, for papers by Émilie Faivre Breakdown of academic impact, for papers by Sravan K. Goparaju Breakdown of academic impact, for papers by Kendra K. Bence Breakdown of academic impact, for papers by Bhumsoo Kim Breakdown of academic impact, for papers by Ronald W. Irwin
Rankless by CCL
2026